CRIS Current Research Information System

PELLEGRINI, CINZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.730
EU - Europa 2.552
AS - Asia 1.494
AF - Africa 158
SA - Sud America 19
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 7.957
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.710
SE - Svezia 580
GB - Regno Unito 569
IT - Italia 525
CN - Cina 482
VN - Vietnam 403
SG - Singapore 380
DE - Germania 335
IN - India 139
IE - Irlanda 105
FR - Francia 91
RU - Federazione Russa 91
TG - Togo 59
UA - Ucraina 57
ZA - Sudafrica 49
EE - Estonia 45
FI - Finlandia 44
JO - Giordania 26
NG - Nigeria 26
CI - Costa d'Avorio 22
CA - Canada 20
BE - Belgio 19
NL - Olanda 15
ID - Indonesia 14
AT - Austria 13
PL - Polonia 12
BG - Bulgaria 10
BR - Brasile 10
IR - Iran 10
CH - Svizzera 9
HK - Hong Kong 8
JP - Giappone 8
HR - Croazia 7
LB - Libano 7
ES - Italia 4
MY - Malesia 4
PE - Perù 4
RO - Romania 4
LT - Lituania 3
PH - Filippine 3
PT - Portogallo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
AU - Australia 2
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
IL - Israele 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
UZ - Uzbekistan 2
BN - Brunei Darussalam 1
BY - Bielorussia 1
DK - Danimarca 1
EC - Ecuador 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
OM - Oman 1
PK - Pakistan 1
RS - Serbia 1
Totale 7.957
Salva come PNG Salva come JPEG
Città #
Southend 504
Fairfield 471
Chandler 350
Singapore 338
Ashburn 291
Santa Clara 273
Houston 256
Woodbridge 227
Seattle 217
Wilmington 190
Cambridge 158
Dong Ket 152
Ann Arbor 151
Princeton 145
Boardman 111
Dublin 105
Bologna 79
Berlin 65
Lomé 59
Nanjing 57
Westminster 54
Padova 45
Bremen 43
Milan 42
New York 41
Helsinki 40
Beijing 37
Jinan 37
San Diego 33
Rome 29
Amman 26
Abeokuta 25
Shenyang 25
Hebei 23
Abidjan 22
Jacksonville 22
Saint Petersburg 21
Turin 21
Dearborn 20
Tianjin 20
Los Angeles 19
Brussels 18
Florence 17
Hyderabad 17
Redmond 17
Jiaxing 16
Toronto 16
Changsha 14
Guangzhou 14
Nanchang 14
Taizhou 14
Jakarta 13
Shanghai 13
Zhengzhou 13
Redwood City 11
Catania 10
Des Moines 10
Olalla 9
Vienna 9
Warsaw 9
Bern 8
Hangzhou 8
Paris 8
Phoenix 8
Bühl 7
Casalecchio di Reno 7
London 7
Mülheim 7
Ningbo 7
Reggio Emilia 7
Sofia 7
Tokyo 7
Andover 6
Fuzhou 6
Haikou 6
Modena 6
Norwalk 6
Amsterdam 5
Falconara Marittima 5
Hong Kong 5
Verona 5
Chengdu 4
Cinisello Balsamo 4
Kuala Lumpur 4
Lanzhou 4
Lappeenranta 4
Monmouth Junction 4
Nova Milanese 4
Nuoro 4
Nuremberg 4
Parma 4
Quanzhou 4
Riolo Terme 4
San Felice sul Panaro 4
San Francisco 4
Shenzhen 4
São Paulo 4
Wuhan 4
Zanjan 4
Aversa 3
Totale 5.311
Salva come PNG Salva come JPEG
Nome #
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 240
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 222
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 197
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 182
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 164
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 156
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 154
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 153
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 153
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 153
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 151
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 150
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 150
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 145
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 145
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 144
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 136
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 132
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 130
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 129
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 126
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 125
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 124
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 124
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 120
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 120
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 120
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 119
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 118
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 117
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 116
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 116
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 116
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 115
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 115
Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report 114
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 110
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 108
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 107
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 107
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 106
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 105
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 104
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 103
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program 101
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 101
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 101
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 99
Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome? 98
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 97
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 94
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 91
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 88
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 85
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 85
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 78
Mycosis fungoides: disease evolution of the "lion queen" revisited. 76
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 71
null 69
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 66
Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma 66
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 64
Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience 63
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 62
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 59
Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report 46
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 44
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 44
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 41
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 39
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study 38
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 35
Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report 33
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 28
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 24
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 24
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 23
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report 22
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 20
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 18
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma. 16
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients 14
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 11
Totale 8.175
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.250
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.250
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.042 0 0 0 0 0 0 217 242 270 127 86 100
2020/20211.006 162 52 38 24 18 43 3 43 120 32 56 415
2021/20221.428 165 63 93 156 110 67 29 92 52 88 284 229
2022/20231.587 161 240 117 220 122 123 35 119 231 45 97 77
2023/2024510 39 83 32 48 39 59 39 32 19 54 25 41
2024/20251.352 106 300 211 183 402 145 5 0 0 0 0 0
Totale 8.175